Also listed under Myeloproliferative Disorders
ClinicalTrials.gov term: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic Myeloid Leukemia (CML) clinical trials
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-08
What changed in the last 30 days
20 trials changed in the last 30 days: 1 stopped, 10 with notable changes, 9 with minor changes only.
- Minor: K2SPIRIT · Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Enrolling by Invitation
- Stopped: Hu8F4 · Advanced Hematologic Malignancies Trial terminated
- Minor: Collecting Blood Samples From · and Without Cancer to Evaluate Tests for Early Cancer Detection Trial sites expanded: 747 → 751 locations
- Minor: Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens · Hematologic Malignancies Start date changed from estimate of Nov 4, 2026 to Oct 28, 2026
- Notable: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) Primary completion pushed from Sep 2026 to Sep 2027
- Notable: Prophylactic DLI-X for Leukemia Relapse After HCT Recruitment opened
- Notable: Allow Access to Imatinib · on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator Results posted: Oct 29, 2026
- Minor: Allogeneic iNKT Cell Therapy (agenT-797) After SCT Start date pushed from Oct 2026 to Nov 2026
- Minor: Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation · High-Risk Hematologic Diseases Interventions modified
- Notable: Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Primary and study completion dates pushed to Feb 14, 2030
- Notable: CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors · CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant Primary completion moved earlier from Jan 1, 2028 to Jan 1, 2027
- Minor: Cord Blood Transplant · Blood Cancers Enrollment closed, study ongoing
- Minor: ASC4Young · Asciminib Safety and Efficacy in Young · Chronic Myeloid Leukemia in the Gulf Region Primary and study completion pushed from Jun 30, 2027 to Jul 30, 2027
- Notable: TGRX-678 US Phase I for Chronic Myelogenous Leukemia Patients Primary completion pushed from Mar 30, 2027 to Dec 31, 2027
- Notable: CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation Study completion date changed from estimate of Dec 31, 2025 to Sep 8, 2026
- Minor: Condition Vasoregulation Function Endothelium · CML Getting TKI II Generation Bosutinib Trial completed
- Notable: CARDINAL · MK-4208/TERN-701 · Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL) Enrollment increased: 180 → 330 participants
- Minor: Asciminib · Ph+ CML-CP Trial sites expanded: 30 → 34 locations
- Notable: Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy Primary and study completion dates pushed to Jun 2027
- Notable: PHARM-LMC · Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia Primary completion pushed from Nov 1, 2025 to Dec 31, 2027
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New sponsor entrants, last 90 days sponsors with their first trial in this area
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-14 | NCT07872709 Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms | John Mascarenhas new | Phase 2 |
| 2026-09-10 | NCT07814170 A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In… | University of West Attica new | |
| 2026-09-04 | NCT07804901 Asciminib Frontline Risk Adapted | Prof. Dr. med. Andreas Hochhaus new | Phase 2 |
| 2026-08-11 | NCT07758218 Allogeneic iNKT Cell Therapy (agenT-797) After SCT | University of Wisconsin, Madison new | Phase 1 |
Active trials by phase
| Early Phase 1 | 1 | |
| Phase 1 | 33 | |
| Phase 1/2 | 12 | |
| Phase 2 | 66 | |
| Phase 3 | 9 | |
| Phase 4 | 3 |
Not charted: 55 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Top sponsors by active trials in this area
M.D. Anderson Cancer Center (18) · Novartis Pharmaceuticals (15) · City of Hope Medical Center (7) · Fred Hutchinson Cancer Center (5) · Assiut University (4) · Baylor College of Medicine (4) · Center for International Blood and Marrow Transplant Research (4) · Shenzhen TargetRx Co., Ltd. (4) · Enliven Therapeutics (3) · Gruppo Italiano Malattie EMatologiche dell'Adulto (3)
Get alerts when Chronic Myeloid Leukemia (CML) trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.